US RE50642 (United States) Drug Patent Landscape: Claim Scope, Coverage Logic, and Competitive Positioning
What does RE50642 claim, at the method-combination level?
RE50642 is a US reissue-style patent that claims methods of treating male humans with non-metastatic castration-resistant prostate cancer (nmCRPC) using a specific AR-directed anti-androgen in combination with a GnRH agonist (or in some dependent claim variants, with detailed patient criteria and dosing schedules). The independent claim set is built around a treatment method that is (i) nmCRPC, (ii) anti-androgen dose within a defined mg/day range, and (iii) co-administration of a GnRH agonist.
Core independent claim elements (representative)
Across claim families, the required elements are:
- Indication: “non-metastatic castration-resistant prostate cancer” in a male human
- Therapeutic backbone: administration of an anti-androgen of one of three enumerated structures
- Dose window: “about 30 mg per day to about 480 mg per day”
- Combination requirement: administering a GnRH agonist
- Administration modality: in many dependent claims, oral dosing and/or continuous daily schedule
Three enumerated anti-androgens (claim term scope)
The claims list three specific anti-androgen chemical entities. They are treated as interchangeable for purposes of the independent claim “wherein the anti-androgen is:” limitation.
| Claim scope |
Anti-androgen identity in the claims |
| Anti-androgen variant A |
4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2 fluoro-N-methylbenzamide |
| Anti-androgen variant B |
4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide |
| Anti-androgen variant C |
4-[7-[4-cyano-3-(trifluoromethyl)phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide |
In dependent claims, variant A is explicitly tied to ARN-509 in multiple places, including oral dosing embodiments (e.g., “ARN-509 is administered orally” at specific daily doses).
What is the claimed treatment combination and what dosing ranges matter?
What dose ranges and dose specifics constrain infringement risk?
Independent claim dose window
- “about 30 mg per day to about 480 mg per day” is a broad numerical range in the independent claim structure.
Dependent claim dose anchors
The dependent claims tighten the oral-dosing and dose-selection into specific mg/day points for variant A (ARN-509) and for select other variants:
- Variant A (ARN-509) oral dosing options (dependent claims):
- about 30 mg/day
- about 60 mg/day
- about 90 mg/day
- about 120 mg/day
- about 240 mg/day
- Another dependent claim locks a specific daily dose for variant B:
- Additional independent/variant-specific language states:
- anti-androgen administered in an amount of about 180 mg/day or 120 mg/day
- Further dependent claim variants specify:
- about 180 mg/day
- about 120 mg/day
- Another dependent claims set:
- about 180 mg/day only (claims 55 and 56)
Daily schedule limitation
Several dependent claims require:
- daily administration, and/or
- continuous daily dosage schedule, and/or
- oral administration
Practical coverage logic
Given the independent claim dose window and the existence of multiple dependent claims with narrow dose/route schedule limitations, infringement risk clusters around:
- oral administration of variant A (ARN-509) within the discrete enumerated doses (30, 60, 90, 120, 180, 240 mg/day depending on claim), especially when paired with a GnRH agonist
- nmCRPC patients meeting defined PSA kinetics or high-risk definitions (dependent claim set)
Which GnRH agonists are explicitly within scope?
What GnRH agonist alternatives appear in the claims and how do they expand coverage?
The GnRH agonist element is defined broadly enough that multiple approved GnRH agonists can satisfy the “wherein the GnRH agonist is:” limitation.
Explicit GnRH agonist list in dependent claims
Dependent claims list:
- leuprolide
- buserelin
- naferelin
- histrelin
- goserelin
- deslorelin
These appear repeatedly across multiple claim groupings (including both the main enumerated anti-androgen families and route/dose sub-sets).
What patient subgroups and PSA-based criteria narrow or tailor claims?
What “high risk” and PSA-dynamics limitations exist?
The dependent claims include clinically specified criteria that narrow the “who” of the treatment method.
High risk nmCRPC definition
- “high risk non-metastatic castration-resistant prostate cancer” is recited (dependent claims)
- High-risk is tied to:
- PSADT ≤ 10 months (PSA doubling time)
PSA rise timing event definition
A specific PSA pattern is also claimed:
- “3 consecutive rises of PSA, 1 week apart,” resulting in:
- “two 50% increases over the nadir”
- and “the last PSA > 2 ng/mL”
Testosterone castration maintenance
A further dependent claim requires maintaining androgen deprivation biochemical status:
- “castrate levels of testosterone of less than 50 ng/dL”
Prior treatment history
Several dependent claims recite prior prostate cancer management, including:
- Previously treated with orchiectomy or continuous androgen deprivation therapy (ADT)
When continuous ADT is recited, it includes GnRH agonist or antagonist formulations:
- dependent claim text states continuous ADT “comprises administration of a gonadotropin-releasing hormone (GnRH) agonist or antagonist,” and further specifies GnRH agonist types in a leuprolide/buserelin/naferelin/histrelin/goserelin/deslorelin list.
Dose management events
Two dependent claims tie to adaptive dose management:
- previously treated at 240 mg/day and required:
- dose reduction, or
- dose interruption
These claim elements matter because they can add patent coverage when a sponsor’s label or clinical protocol includes similar management language for ARN-509-type dosing.
What claim types exist: full vs “consisting essentially of” limitations?
How does “consisting essentially of” change claim coverage?
The claims include both:
- “method consisting essentially of” variants, and
- standard method variants.
For a “consisting essentially of” claim, the method permits other steps only if they do not materially change the basic and novel characteristics of the claimed invention. On the face of the claim set, the basic characteristics are:
- nmCRPC
- anti-androgen (one of the three enumerated structures)
- specified dosing and typically oral/continuous embodiments (in dependent claims)
- GnRH agonist co-administration
As a result:
- A generic “add-on” of unrelated therapies could still fall outside if it materially changes the method’s character.
- The claims strongly suggest the intended basic novelty is the anti-androgen + GnRH agonist combination in nmCRPC at the defined dose windows.
How broad is coverage across the three anti-androgen structures?
Is infringement tied to a single compound or multiple structures?
The independent claim structure is compound-flexible within the enumerated set: it covers methods where the anti-androgen is any one of the three defined structures. That matters because a competitor using:
- the same compound (variant A or ARN-509),
- or one of the other enumerated analogs (variants B or C),
can potentially trigger the same method claim architecture if co-administered with GnRH agonist and dosed within the asserted windows.
However, multiple dependent claims explicitly anchor ARN-509 to variant A and provide more granularity for route and dose. That typically concentrates enforceability around variant A, while leaving more general method coverage for the other enumerated analogs.
What is the overall infringement “switchboard” by claim element?
Which combinations are most likely to be captured by the independent structure?
The most likely captured combination scenarios (based solely on the claim text provided) are:
- nmCRPC patients (male)
- receiving one of the three anti-androgens enumerated in the claims
- dosed about 30 to 480 mg/day
- with GnRH agonist co-administration (leuprolide/buserelin/naferelin/histrelin/goserelin/deslorelin)
- with additional risk if the protocol matches:
- oral and/or continuous daily dosing
- high-risk PSA doubling criteria (PSADT ≤ 10 months)
- PSA rise pattern (3 consecutive rises, PSA nadir dynamics, last PSA > 2 ng/mL)
- testosterone < 50 ng/dL maintenance
What is the patent landscape picture for RE50642 specifically?
Where does RE50642 sit in the broader competitive landscape (claims-only assessment)?
Because the prompt provides only RE50642 claim text (and no bibliographic record such as filing date, priority, expiration, related family members, prosecution history, or examiner reissue scope), a complete US patent landscape mapping (continuations, related oppositions, terminal disclaimers, OR reference patents, co-owned families, and forward citations) cannot be produced from the provided data.
What can be stated directly from the claim set:
Landscape conclusions derived from claim structure
- RE50642 is a method-of-treatment patent oriented to the specific combination regimen:
AR-targeting anti-androgen (one of three enumerated structures) + GnRH agonist
- It covers not only general nmCRPC treatment, but also patient stratification (PSADT, PSA kinetics) and dose management (dose reduction/interruption after 240 mg/day).
- It includes both broad and narrower dependent claim layers, implying a strategy to maintain coverage even if a competitor attempts to design around by:
- modifying dose within the independent window
- selecting among GnRH agonists within the enumerated list
- changing route/schedule (though oral/continuous schedule exists in dependent claims)
Competitive implications
A sponsor planning an nmCRPC trial or commercial protocol must assess:
- whether the regimen includes a GnRH agonist from the enumerated set
- whether dosing for the relevant AR agent falls within the about 30 to about 480 mg/day range
- whether patient selection aligns with high risk definitions and PSA trigger events
- whether trial reporting and management reflect the dose reduction/interruption features tied to 240 mg/day
How do the “dose and route” dependent claims affect design-around strategy?
What design-around levers exist on the face of the claims?
The claims create obvious design constraints:
- Oral vs non-oral: some dependent claims require oral administration. A non-oral route might avoid those dependent limitations but not the broader independent method unless route is also required there (independent claim 1 text does not expressly require oral in the excerpt you provided).
- Continuous daily schedule: dependent claims require continuous daily dosing schedules.
- Discrete dose points: several dependent claims list exact “about X mg/day” points. Running outside those discrete values does not necessarily avoid the independent window because the independent claim covers a wide continuum (30 to 480 mg/day).
- GnRH agonist identity: dependent claims restrict examples, but the independent claim requires “administering a GnRH agonist” generically. Using a non-agonist ADT modality would be the principal lever, but dependent claims also include an ADT definition that still points to GnRH agonist/adapted ADT categories.
Key Takeaways
- RE50642 claims nmCRPC treatment methods combining a specific enumerated anti-androgen (three structures listed) with a GnRH agonist.
- The independent dose range is about 30 mg/day to about 480 mg/day, with dependent claims adding discrete oral dose anchors including 30, 60, 90, 120, 160, 180, and 240 mg/day depending on the claim and compound variant.
- GnRH agonist coverage explicitly includes leuprolide, buserelin, naferelin, histrelin, goserelin, and deslorelin.
- Dependent claims add clinical refinement:
- high risk nmCRPC tied to PSADT ≤ 10 months
- PSA rise event criteria (3 consecutive PSA rises 1 week apart; last PSA > 2 ng/mL; two 50% increases over nadir)
- maintenance of testosterone < 50 ng/dL
- prior orchiectomy/continuous ADT history
- dose reduction or interruption after prior 240 mg/day treatment.
- The claim set is structured to preserve enforceability across multiple protocol variations: compound alternative variants, multiple GnRH agonists, and multiple dose-management scenarios.
FAQs
1) Does RE50642 require a specific single anti-androgen?
No. The independent claims cover methods where the anti-androgen is one of three enumerated chemical structures.
2) Is the claimed dose range narrow or broad?
Broad at the independent level: about 30 mg/day to about 480 mg/day. Dependent claims then add narrower dose and regimen specificity.
3) Which GnRH agonists are included?
The claims explicitly include leuprolide, buserelin, naferelin, histrelin, goserelin, and deslorelin.
4) Do the claims require “high risk” PSA criteria?
Not in the independent set. “High risk nmCRPC” with PSADT ≤ 10 months and the specified PSA rise pattern appears in dependent claims.
5) Can a protocol avoid infringement by changing ADT to an antagonist?
The independent claim requires a GnRH agonist, and dependent claims also include ADT language tied to GnRH categories. A clear avoidance would require stepping outside “GnRH agonist” as claimed, but the provided claim text does not supply antagonist-specific exclusions that would be enough to conclude avoidance.
References
[1] United States Patent RE50642, claim text provided in prompt (claims 1-56).
